Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789074 | 0.87 | FABP5 (0.48) | FABP5FABP7EPHX2CA1CA2 | |
| SCHEMBL29430507 | 0.87 | FABP5 (0.48) | FABP5FABP7EPHX2CA1CA2 | |
| SCHEMBL1935691 | 0.84 | CA1 (0.36) | ALBEPHX2CA1CA2TSHR | |
| SCHEMBL4478311 | 0.82 | FABP5 (0.36) | FABP5FABP7EPHX2CA1CA2 | |
| SCHEMBL29178041 | 0.80 | CA1 (0.39) | FABP5FABP7ALBEPHX2CA1 | |
| SCHEMBL4606087 | 0.80 | HRH3 (0.32) | CA1CA2KMT2ATSHR | |
| SCHEMBL3490351 | 0.78 | EPHX2 (0.36) | FABP5FABP7ALBEPHX2CA1 | |
| SCHEMBL1934604 | 0.77 | CA1 (0.43) | FABP5FABP7ALBEPHX2CA1 | |
| SCHEMBL1539602 | 0.77 | CA1 (0.47) | FABP5FABP7ALBEPHX2CA1 | |
| SCHEMBL1934603 | 0.75 | KMT2A (0.43) | FABP5FABP7ALBEPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956295-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| US-20160324975-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-11-10 | — | — | US | disclosed |
| US-9433683-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2016-09-06 | — | — | US | disclosed |
| US-20160000927-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2016-01-07 | — | — | US | disclosed |
| US-9119883-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2015-09-01 | — | — | US | disclosed |
| US-20150057219-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-02-26 | — | — | US | disclosed |
| US-8877709-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-11-04 | — | — | US | disclosed |
| EP-1620118-B1 | REVERSIBLE PEGYLATED DRUGS | YEDA RES & DEV (IL) | 2014-06-18 | — | — | EP | disclosed |
| US-8735350-B2 | Reversible pegylated drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-20140121352-A1 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2014-05-01 | — | — | US | disclosed |
| US-20100041867-A1 | REVERSIBLE PEGYLATED DRUGS | Yeda Reserch and Development Co., Ltd. (IL) | 2010-02-18 | — | — | US | disclosed |
| US-7585837-B2 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-09-08 | — | — | US | disclosed |
| EP-1337270-B1 | LONG-ACTING INTERFERON AND INTERLUKIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RES & DEV (IL) | 2008-07-16 | — | — | EP | disclosed |
| US-20060171920-A1 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2006-08-03 | — | — | US | disclosed |
| EP-1620118-A2 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2006-02-01 | — | — | EP | disclosed |
| EP-1337270-A4 | LONG-ACTING CYTOKINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RES & DEV (IL) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004089280-A2 | REVERSIBLE PEGYLATED DRUGS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-10-21 | — | — | WO | disclosed |
| US-20040131586-A1 | Long-acting cytokine derivatives and pharmaceutical compositions comprising them | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-07-08 | — | — | US | disclosed |
| EP-1337270-A2 | LONG-ACTING CYTOKINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002036067-A2 | LONG-ACTING CYTOKINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057219-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | FABP5 324/4885FABP7 112/4885ALB 125/4885 |
| US-20060171920-A1 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | PTMS, FIBP, FLT3 | FABP5 159/4885FABP7 45/4885ALB 163/4885 |
| US-20100041867-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | FABP5 324/4885FABP7 112/4885ALB 125/4885 |
| US-20140121352-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | FABP5 324/4885FABP7 112/4885ALB 125/4885 |
| US-20040131586-A1 | Long-acting cytokine derivatives and pharmaceutical compositions comprising them | IL2, IFNG, CSF3R | FABP5 887/4885FABP7 96/4885ALB 1810/4885 |
| US-20160324975-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | FABP5 324/4885FABP7 112/4885ALB 125/4885 |
| US-20160000927-A1 | REVERSIBLE PEGYLATED DRUGS | PTMS, FIBP, FLT3 | FABP5 324/4885FABP7 112/4885ALB 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.